Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.

Parikh, Ravi B; Hubbard, Rebecca A; Wang, Erkuan; Royce, Trevor J; Cohen, Aaron B; Clark, Amy S; Mamtani, Ronac

Parikh, Ravi B; Hubbard, Rebecca A; Wang, Erkuan; Royce, Trevor J; Cohen, Aaron B; Clark, Amy S; Mamtani, Ronac.

Afiliação

Parikh RB; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Hubbard RA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Wang E; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Royce TJ; Flatiron Health, New York, New York.
Cohen AB; Flatiron Health, New York, New York.
Clark AS; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Mamtani R; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

JAMA Oncol ; 9(4): 567-569, 2023 04 01.

Article em En | MEDLINE | ID: mdl-36821118

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Assuntos

Antineoplásicos; Neoplasias; Estados Unidos; Humanos; United States Food and Drug Administration; Antineoplásicos/efeitos adversos; Aprovação de Drogas; Neoplasias/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Prevencao_e_fatores_de_risco / Agentes_cancerigenos / Alimentacao / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Tipo de estudo: Observational_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: JAMA Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google